Collaboration Addresses Renal-Specific Testing Services

New York, NY (January 28, 2010)

–

Clinilabs

, a contract research organization (CRO) specializing in early phase and specialty studies, is proud to announce that the Company has formed a collaboration with the Renal Research Institute, LLC (RRI), with headquarters in New York. This collaboration allows Clinilabs and the RRI to provide a high level of clinical drug development services to pharmaceutical and biotechnology companies.  The collaboration includes Spectra Clinical Research, a division of Spectra Laboratories, the leading provider of renal-specific testing services in the United States.
 
Founded in 1997,

Renal Research Institute

, LLC is dedicated to advancing therapy options for dialysis patients to provide the highest caliber of care based on advanced clinical technology. RRI enhances the quality of comprehensive renal services by advancing peritoneal and hemodialysis therapies through clinical research and the application of practice guidelines and new technology.  

Spectra Clinical Research

provides central clinical laboratory services for clinical trials, fusing the strength of a major laboratory facility with the responsiveness and dedication of a small, specialized team.  
 
Dr. Gary K. Zammit, President & CEO of Clinilabs Inc., states, “Clinilabs is pleased announce its collaboration with the Renal Research Institute, LLC and Spectra Clinical Research.  These alliances will enable us to complete studies in patients with renal impairment at our 48-bed phase 1 unit in New York; studies that are essential to early phase drug development.  Our ability to bring three top organizations together in collaboration represents an important new offering for industry-sponsored research.”